Lipids & metabolic liver disease
The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study
Authors' conclusion
Among individuals with MASLD, CHG-related indices, particularly CHG-WHtR and CHG-WC, were associated with incident CMM and transition-specific disease progression and improved risk prediction.
Study context
- Population
- UK Biobank participants with MASLD and without T2D, coronary heart disease (CHD) or stroke at baseline
- Participants
- 109,434 participants
- Exposure
- Per 1-SD increment in CHG-related indices
- Outcome
- Incident CMM (at least two of T2D, CHD and stroke)
- Follow-up
- Median 16.4 years
Methodological detailsUK Biobank, multistate models, exploratory mediation analyses
- UK Biobank
- Multistate models
- Exploratory mediation analyses
Main finding
As reported in the abstract
Incident CMM
Hazard ratio (95% CI)
CHG-WHtR, per 1-SD increment
1.61(1.57–1.65)
CHG-WC, per 1-SD increment
1.59(1.55–1.63)
Per 1-SD increment, as printed
- Participants who developed cardiometabolic multimorbidity (CMM)
- 4225
Observational data: associations, not effects.
Further findings
Incremental risk prediction
- Adding each index to conventional risk models improved discrimination and risk classification; CHG-waist-to-height ratio (CHG-WHtR) and CHG-waist circumference (CHG-WC) relatively favorable, absolute differences between indices modest
Multistate transitions
- Associations strongest for disease-free to T2D and CHD-to-CMM transitions
Exploratory biomarker analyses
- Biomarker domains of glycemic regulation, lipid metabolism, inflammation, hepatic and renal function statistically linked to the associations
- Exploratory
Original publication
The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study. Cardiovasc Diabetol. Published 23 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →